Header Images
 
 
 
 

ITOR Clinical Research Unit Active Studies

The ITOR Clinical Research Unit (CRU) is committed to conducting ongoing studies of leading-edge therapies and research for new cancer treatments.

The unit specializes in molecular-driven solid tumor trials, and averages 20 or more active trials at any given time.

Trials currently available are listed below:
Note: Please contact us for questions and additional information.

Solid Tumors

  • A phase Ib, muti-center, two parallel group, open label, drug-drug interaction study to evaluate the effect of LDE225 on the PKs of bupropion (Wellbutrin)
  • A phase 1 Clinical Study of BBI608 in Adult Patients with Advanced hematologic malignancies
  • A dose finding, open label, phase I study of RX-5902 in subjects with advanced or metastatic solid tumors *FIRST IN MAN trial*
  • Phase I, Open-Label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PKs, Biological and Clinical Activity of MSB0010718C in Subjects with Melanoma, NSCLC, Adrenal corticol, Mesothelioma, urothelial bladder and Gastric ca
  • Phase I, Open-Label, Mulitceter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivvalence of CC-486 (Oral Azacitidine)Tablets in Adult Cancer Subjects
  • A Phase I Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
  • A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (PI-Edenfield) (CRU ONLY-Lisa 455-3735 or Jill 455-3737) Enrolling in Part 1 currently

Bladder

  • A Phase 1 study of MEDI4736 (Anti-PD-L1 Antibody) in combination with Tremelimumab (Anti-CTLA-4 Antibody) in subjects with transitional cell bladder cancer, ext SCLC, STS, TNBC or HPV-positive anogenital cancer (anal, cervical and vaginal)

Breast

  • A Phase 1 study of MEDI4736 (Anti-PD-L1 Antibody) in combination with Tremelimumab (Anti-CTLA-4 Antibody) in subjects with transitional cell bladder cancer, ext SCLC, STS, TNBC or HPV-positive anogenital cancer (anal, cervical and vaginal)

Colon

  • A Phase II Clinical Study of BBI608 in Adult Patients with Advanced Colorectal Cancer

GI

  • A Phase IB clinical study of BBI608 in combination with standard chemotherapies in adult patients with advanced gastrointestinal cancer
  • A Phase 1b/2 Study of MED14736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with metastatic or recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

GYN

  • Phase I, dose escalation, and PK study of Prolanta SQ in patients with recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer, or fallopian cancer.

Head/Neck

  • A phase 1 study to evaluate the safety, tolerability and efficacy of MED14736 in combination with Tremelimumab or Tremelimumab alone in subjects with recurrent or met squamous cell carcinoma of the head and neck **ON HOLD- no available slots**

Hematologic

  • A Phase 1b/2 Proof-of-concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with B-Cell Malignancies
  • A Phase 2, Multicenter, Randomized, Open-Label, Parallel-Group Study of Lenalidomide Regimen or a Sequential Azacitidine Plus Lenalidomide Regimen Versus and Azacitidine Regimen for Therapy of Older Subjects with Newly Diagnosed Acute Myeloid Leukemia

Liver

  • A Phase Ib, Multicenter, Open-Label, Dose Finding Study of CC-122 in Combination with Sorafenib in Subjects with Unresectable Hepatocellular Carcinoma

Small Cell Lung

  • A Phase 1b/2 study of OMP-59R5 in combination with Etoposide and Cisplatin in subjects with untreated extensive stage SCLC
  • A Phase 1 study of MEDI4736 in combination with Tremelimumab in subjects with transitional cell bladder cancer, ext SCLC, STS, TNBC or HPV-positive anogenital cancer **call for slot availibility**
  • Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy

Melanoma

  • A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

NSCLC

  • A Phase I, multi-center, randomized open label study to assess the systemic exposure and safety of 450 mg ceritinib taken with a low-fat meal and 600mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer
  • A Phase Ib Study of the safety and pharmacology of MPDL3280Aadministered with erlotinib or alectinib in patients with advanced non-small cell lung cancer

Pancreas

  • A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer
  • A Phase I/2 Study of Indoximod in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas

Relapsed/Refractory Met Pancreatic Cancer

  • A Phase 1b Study of Single Agent Idelalisib (Zydelig) Followed by Idelalisib in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

Prostate

  • An Open-label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer

Renal

  • A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma

Sarcoma

  • A Phase 1 study of MEDI4736 (Anti-PD-L1 Antibody) in combination with Tremelimumab (Anti-CTLA-4 Antibody) in subjects with transitional cell bladder cancer, ext SCLC, STS, TNBC or HPV-positive anogenital cancer (anal, cervical and vaginal)